Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma

• Published in: Hepatology (Baltimore, Md.) Vol. 64; no. 5; pp. 1637 - 1651
• Main Authors: Chen, Hsin‐An, Kuo, Tsang‐Chih, Tseng, Chi‐Feng, Ma, Jui‐Ti, Yang, Shu‐Ting, Yen, Chia‐Jui, Yang, Ching‐Yao, Sung, Shian‐Ying, Su, Jen‐Liang
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.11.2016
• Subjects: AKT protein; Angiogenesis; Angiopoietin; Angiopoietin-like Proteins; Angiopoietins - physiology; Animals; Antineoplastic Agents - therapeutic use; Carcinoma, Hepatocellular - drug therapy; Drug Resistance, Neoplasm; EGR-1 protein; Extracellular signal-regulated kinase; Female; Hepatocellular carcinoma; Hepatology; Humans; Inhibitor drugs; Kinases; Liver cancer; Liver Neoplasms - drug therapy; Male; Mesenchyme; Metastases; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Phenylurea Compounds - therapeutic use; Proteins; Proto-Oncogene Proteins c-met - physiology; Stem cells; Targeted cancer therapy; Tumor suppressor genes

Angiopoietin‐like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis. However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mecha...